Veradigm (MDRX) Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veradigm in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDRX, but not buy additional shares or sell existing shares.
View MDRX analyst ratings or view top-rated stocks.

6 Wall Street analysts have issued 12 month price objectives for Veradigm's stock. Their MDRX share price forecasts range from $13.00 to $26.00. On average, they expect the company's stock price to reach $19.58 in the next twelve months. This suggests a possible upside of 66.2% from the stock's current price.
View analysts price targets for MDRX or view top-rated stocks among Wall Street analysts.

Veradigm's stock was trading at $17.64 at the beginning of 2023. Since then, MDRX stock has decreased by 33.2% and is now trading at $11.78.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 1st 2023.
View our MDRX earnings forecast.

Veradigm Inc. (NASDAQ:MDRX) announced its quarterly earnings data on Thursday, November, 4th. The software maker reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.09. The software maker had revenue of $369 million for the quarter, compared to analyst estimates of $376.09 million. Veradigm had a trailing twelve-month return on equity of 10.74% and a net margin of 7.25%. Veradigm's revenue was down 8.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.15 earnings per share.

ETFs with the largest weight of Veradigm (NASDAQ:MDRX) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Invesco Dynamic Software ETF (PSJ), Fidelity Digital Health ETF (FDHT), Harbor Health Care ETF (MEDI), Invesco S&P SmallCap Health Care ETF (PSCH), Cambria Shareholder Yield ETF (SYLD), Pacer US Small Cap Cash Cows 100 ETF (CALF) and First Trust Active Factor Small Cap ETF (AFSM).

Veradigm issued an update on its FY 2023 earnings guidance on Wednesday, March, 22nd. The company provided earnings per share (EPS) guidance of $0.80-$0.90 for the period, compared to the consensus estimate of $0.90. The company issued revenue guidance of $615.00 million-$635.00 million, compared to the consensus revenue estimate of $649.05 million.

796 employees have rated Veradigm Chief Executive Officer Paul Black on Glassdoor.com. Paul Black has an approval rating of 65% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Veradigm investors own include Advanced Micro Devices (AMD), Netflix (NFLX), Energy Transfer (ET), CVS Health (CVS), Ford Motor (F), Himax Technologies (HIMX), Intel (INTC), OPKO Health (OPK), Tesla (TSLA) and Activision Blizzard (ATVI).

Veradigm trades on the NASDAQ under the ticker symbol "MDRX."

Veradigm's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (18.73%), Dimensional Fund Advisors LP (8.34%), State Street Corp (3.63%), William Blair Investment Management LLC (3.13%), Fisher Asset Management LLC (2.68%) and Geode Capital Management LLC (2.00%). Insiders that own company stock include David B Stevens, Elaina Shekhter, Elizabeth Ann Altman, Greg Garrison, Leah Jones, Lisa Khorey, Michael Klayko, Paul Black, Richard J Poulton, Tejal Vakharia and Thomas Langan.
View institutional ownership trends.

Shares of MDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MDRX stock can currently be purchased for approximately $11.78.

Veradigm (NASDAQ:MDRX) has a market capitalization of $1.29 billion and generates $1.50 billion in revenue each year. The software maker earns $134.44 million in net income (profit) each year or $0.43 on an earnings per share basis.

The company employs 8,000 workers across the globe.

Veradigm's mailing address is 222 MERCHANDISE MART PLAZA SUITE 2024, CHICAGO IL, 60654. The official website for the company is www.allscripts.com. The software maker can be reached via phone at (800) 334-8534, via email at stephen.shulstein@allscripts.com, or via fax at 313-322-9600.